explore -WSS

explore

author：knowledge 2025-10-02 11:08:58 - browse：2

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

explore

WSS

Prior authorization will have to move faster under new Biden rule

Test for long Covid? Researchers find new clue in blood samples

Listen: Vivek Ramaswamy's star turn & leaky drug data

National associations that represent hospice owe an apology

New brain studies show LSD's effects on the brain in full color

Elizabeth Holmes banned from government health programs

focus

explore

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

The surgeon had a dilemma only a Nazi medical text could resolve

Cancer drug shortages should be causing more outrage

Trans patients at the end of life deserve respect and dignity

Alkermes shareholders re

Readout Newsletter: Merck, J&J, and long Covid

Wildfire smoke exposes gaps in outdoor worker protections

How the first Native Hawaiian psychiatrist helped diversify medicine

At least 13 dead in Texas as scorching temps continue

Research misconduct: Proposed new rules face resistance

entertainment

Medicare Advantage today, explained in one chart

My yearlong odyssey to get my son’s ADHD medication covered

Prior authorization will have to move faster under new Biden rule

The surgeon had a dilemma only a Nazi medical text could resolve

FDA greenlights medical device to combat bladder issues

FDA advisory panel to debate high blood pressure devices

focus

hotspot

explore

explore